ADD-ON PEGINTERFERON ALFA-2A SIGNIFICANTLY REDUCES HBsAg LEVELS IN HBeAg-NEGATIVE, GENOTYPE D CHRONIC HEPATITIS B PATIENTS FULLY SUPPRESSED ON NUCLEOT(S)IDE ANALOGUE TREATMENT: THE HERMES STUDY

被引：6
|
作者：
Lampertico, P. [1 ]
Brunetto, M. R. [2 ]
Craxi, A. [3 ]
Gaeta, G. B. [4 ]
Rizzetto, M. [5 ]
Palmieri, G. [6 ]
Colombo, M. [1 ]
机构：
[1] Univ Milan, Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy
[2] Univ Hosp Pisa, Liver Unit, Reference Ctr Chron Liver Dis & HCC Tuscany Reg, Pisa, Italy
[3] Univ Palermo, DiBiMIS, Gastroenterol & Hepatol, Palermo, Italy
[4] Univ Naples 2, Sect Infect Dis & Viral Hepatitis, Dept Internal Med, Naples, Italy
[5] Univ Turin, Dept Gastroenterol, Turin, Italy
[6] Roche, Monza, Italy
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)30179-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LP25
引用
收藏
页码：S276 / S276
页数：1
相关论文
共 50 条
  • [41] A prospective study of nucleot(s)ide analogue discontinuation in non-cirrhotic HBeAg-negative chronic hepatitis B patients: interimanalysis at week 48 demonstrates profound reductions of HBsAg associated with ALT flare
    Hall, Samuel
    Burns, Gareth
    Levy, Miriam
    Lubel, John
    Nicoll, Amanda
    Matthews, Gail
    Desmond, Paul
    Sievert, William
    Bowden, Scott
    Locarnini, Stephen
    Holmes, Jacinta
    JOURNAL OF HEPATOLOGY, 2020, 73 : S69 - S70
  • [42] SERUM HBSAG LEVELS DURING PEGINTERFERON ALFA-2A TREATMENT IN HBEAG-POSITIVE CHRONIC HEPATITIS B: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
    Kim, Bo Hyun
    Kim, Won
    Song, Fun Young
    Park, Myoung Hee
    Yoon, Jung-Hwan
    Lee, Youn Jae
    Park, Sung Jae
    Jung, Eun Uk
    Kim, Donghee
    Kim, Yoon Jun
    Lee, Hyo-Suk
    HEPATOLOGY, 2010, 52 (04) : 514A - 514A
  • [43] RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS
    Lampertico, P.
    Vigano, M.
    Di Costanzo, G. G.
    Sagnelli, E.
    Fasano, M.
    Di Marco, V.
    Boninsegna, S.
    Farci, P.
    Fargion, S.
    Giuberti, T.
    Rothe, V.
    Regep, L.
    Caputo, A.
    Facchetti, F.
    Colombo, M.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S207 - S208
  • [44] Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs
    Ouzan, Denis
    Penaranda, Guillaume
    Joly, Helene
    Khiri, Hacene
    Pironti, Antonnella
    Halfon, Philippe
    JOURNAL OF CLINICAL VIROLOGY, 2013, 58 (04) : 713 - 717
  • [45] BASELINE HBSAG AS PREDICTOR FOR HBSAG SEROCONVERSION IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A AND ADEFOVIR: FINAL RESULTS OF A PROSPECTIVE OPEN LABEL STUDY
    Takkenberg, Bart
    de Niet, Annikki
    Zaaijer, Hans L.
    Weegink, Christine J.
    Terpstra, Valeska
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Rijckborst, Vincent
    Janssen, Harry L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2011, 54 : 1039A - 1040A
  • [46] ON-TREATMENT PREDICTION OF SUSTAINED RESPONSE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGYLATED INTERFERON ALFA-2A
    Rijckborst, Vincent
    Hansen, Bettina E.
    Tabak, Fehmi
    Raptopoulou-Gigi, Maria
    Ormeci, Necati
    Simon, Krzysztof
    Akarca, Ulus S.
    Flisiak, Robert
    Vafiadis-Zouboulis, Irini
    Tripi, Silvio
    Verhey, Elke
    ter Borg, Martijn
    van Vuuren, Anneke J.
    Janssen, Harry L.
    HEPATOLOGY, 2009, 50 (04) : 539A - 540A
  • [47] EXTENDED (2 YEARS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IMPROVES SUSTAINED RESPONSE RATES IN GENOTYPE D-PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B
    Lampertico, P.
    Vigano, M.
    Di Costanzo, G.
    Sagnelli, E.
    Fasano, M.
    Di Marco, V.
    Boninsegna, S.
    Farci, P.
    Fargion, S.
    Giuberti, T.
    Iannacone, C.
    Massetto, B.
    Fedeli, P.
    Colombo, M.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S45 - S45
  • [48] HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS
    Goulis, I.
    Akriviadis, E.
    Karatapanis, S.
    Deutsch, M.
    Dalekos, G.
    Raptopoulou-Gigi, M.
    Mimidis, K.
    Germanidis, G.
    Triantos, C.
    Drakoulis, C.
    Chounta, A.
    Tsoplou, F.
    Zintzaras, E.
    Bakalos, G.
    Papatheodoridis, G.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S201 - S202
  • [49] On treatment prediction of post-treatment sustained response to Peginterferon alfa-2a for HBeAg-negative Chronic Hepatitis B (CHB) patients using HBsAg and HBV DNA levels at weeks 12 and 24: PERSEAS cohort final results
    Goulis, Ioannis
    Karatapanis, Stylianos
    Akriviadis, Evangelos A.
    Deutsch, Melanie
    Dalekos, George N.
    Raptopoulou-Gigi, Maria
    Mimidis, Konstantinos
    Germanidis, Georgios
    Triantos, Christos K.
    Drakoulis, Christos
    Chounta, Athina
    Vafiadis, Irene
    Hatzis, Grigorios
    Gagalis, Asterios
    Vlachogiannakos, Jiannis
    Zintzaras, Elias
    Koulouris, Sokratis
    Bakalos, George
    Papatheodoridis, George V.
    HEPATOLOGY, 2013, 58 : 697A - 698A
  • [50] PEGINTERFERON TREATMENT REDUCES INTRAHEPATIC HBSAG AND HBCAG EXPRESSION IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: RELATION TO SERUM HBSAG DECLINE AND LONG-TERM RESPONSE
    Rijckborst, Vincent
    Zondervan, Pieter E.
    Cakaloglu, Yilmaz
    Raptopoulou-Gigi, Maria P.
    Tabak, Fehmi
    Akdogan, Meral
    Simon, Krzysztof
    Ferenci, Peter
    Verhey, Elke
    Hansen, Bettina E.
    Janssen, Harry L.
    HEPATOLOGY, 2011, 54 : 1026A - 1027A
12345